Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Exelixis Inc

EXEL
Current price
22.43 USD +0.59 USD (+2.70%)
Last closed 21.94 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 822 770 176 USD
Yield for 12 month +30.26 %
Week
Month
Year
EXEL
21.11.2021 - 28.11.2021

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Address: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502

Analytics

WallStreet Target Price

25.82 USD

P/E ratio

75.6552

Dividend Yield

2.47 %

Current Year

+1 611 062 000 USD

Last Year

+1 434 970 000 USD

Current Quarter

+471 920 000 USD

Last Quarter

+469 848 000 USD

Current Year

+1 553 153 000 USD

Last Year

+1 382 097 000 USD

Current Quarter

+453 146 000 USD

Last Quarter

+452 143 000 USD

Key Figures EXEL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 66 156 000 USD
Operating Margin TTM -3.73 %
PE Ratio 75.6552
Return On Assets TTM 0.86 %
PEG Ratio 2.0432
Return On Equity TTM 3.81 %
Wall Street Target Price 25.82 USD
Revenue TTM 1 774 472 960 USD
Book Value 7.55 USD
Revenue Per Share TTM 5.51 USD
Dividend Share
Quarterly Revenue Growth YOY 14.6 %
Dividend Yield 2.47 %
Gross Profit TTM 1 553 153 000 USD
Earnings Share 0.29 USD
Diluted Eps TTM 0.29 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -98.6 %
Profit Margin 5.19 %

Dividend Analytics EXEL

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History EXEL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 2.47 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation EXEL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 75.6552
Forward PE 21.322
Enterprise Value Revenue 3.3325
Price Sales TTM 3.845
Enterprise Value EBITDA 89.385
Price Book MRQ 2.9076

Financials EXEL

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators EXEL

For 52 weeks

15.32 USD 22.8 USD
50 Day MA 21.24 USD
Shares Short Prior Month 9 263 984
200 Day MA 19.95 USD
Short Ratio 3.64
Shares Short 9 700 092
Short Percent 3.57 %